Author:
Cheng Jiangting,Lin Min,Chu Man,Gong Longyuan,Bi Yanli,Zhao Yongchao
Abstract
AbstractThe F-box protein 22 (FBXO22), one of F-box proteins, has been identified to be critically involved in carcinogenesis. FBXO22 promotes proliferation in breast cancer and lung cancer, but suppresses migration and metastasis. FBXO22 exerts oncogenetic functions via promoting the ubiquitination and degradation of its substrates, including KDM4A, KDM4B, methylated p53, p21, KLF4, LKB1, Snail, CD147, Bach1, PTEN, and HDM2. FBXO22 is also regulated by several regulatory factors such as p53, miR-155, SNHG14, and circ_0006282. In this review, we summarize the regulatory factors and downstream targets of FBXO22 in cancers, discuss its functions in tumorigenesis, and further highlight the alteration of FBXO22 expression in a variety of human malignancies. Finally, we provide novel insights for future perspectives on targeting FBXO22 as a promising strategy for cancer therapy.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference51 articles.
1. Liu, J., Qian, C. & Cao, X. Post-translational modification control of innate immunity. Immunity 45, 15–30 (2016).
2. Vu, L. D., Gevaert, K. & De Smet, I. Protein language: post-translational modifications talking to each other. Trends Plant Sci. 23, 1068–1080 (2018).
3. Hirano, A., Fu, Y. H. & Ptacek, L. J. The intricate dance of post-translational modifications in the rhythm of life. Nat. Struct. Mol. Biol. 23, 1053–1060 (2016).
4. Murn, J. & Shi, Y. The winding path of protein methylation research: milestones and new frontiers. Nat. Rev. Mol. Cell Biol. 18, 517–527 (2017).
5. Han, Z. J., Feng, Y. H., Gu, B. H., Li, Y. M. & Chen, H. The post-translational modification, SUMOylation, and cancer (Review). Int J. Oncol. 52, 1081–1094 (2018).
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献